Custom p/q type calcium channel CAV2.1 cell lines
Ended Purchase Order Awarded Last action
- Contract number
- 75N95023P00373
- Awardee
-
Dexorgen Inc. UEI ZNUMJ4FKRC19
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $35,025
Award facts
- Opportunity
-
- Custom P/Q type calcium channel CaV2. 1 cell lines Solicitation · 75N95023Q00290 · Posted Jun 9, 2023
- Contract value 100% obligated
- $35,025.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Montgomery Village, MD 20879, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Original award | $35,025 |
About this award
The National Institutes of Health's National Center for Advancing Translational Sciences awarded a $35,025 firm fixed price purchase order to Codex Biosolutions Inc. under a non-competitive solicitation. Codex will generate a stable P/Q type calcium channel CaV2.1 cell line by cloning specified channel proteins into HEK293 cells and introducing an additional channel to control calcium flux, as described in the attached statement of work. The one-year contract has a period of performance from June to November 2023 and was awarded on the basis of Codex's proprietary fluorescent calcium dye and analytical equipment for monitoring calcium channel activity. There are no set-aside provisions associated with this small business contract for specialized cell line development services in support of translational biomedical research.
Quick answers
Who was awarded contract 75N95023P00373?
75N95023P00373 was awarded to Dexorgen Inc. by National Institute on Drug Abuse (National Institutes of Health) on June 26, 2023.
How much is contract 75N95023P00373 worth?
The government has obligated $35,025 on 75N95023P00373.
Which agency awarded contract 75N95023P00373?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95023P00373, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Was contract 75N95023P00373 competed?
The extent of competition for 75N95023P00373 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award